These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3155282)

  • 1. Effects of changes in brain 5-HT activity on indicators of cortical arousal.
    Rammsayer T; Netter P
    Int Clin Psychopharmacol; 1988 Jul; 3(3):231-7. PubMed ID: 3155282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personality related differences in response to 5-HT uptake inhibition.
    Rammsayer T; Netter P
    Int J Neurosci; 1990 Dec; 55(2-4):99-106. PubMed ID: 2128079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotoninergic effects on sensory and motor responses in extraverts and introverts.
    Netter P; Rammsayer T
    Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():21-6. PubMed ID: 2492574
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of zimeldine, a selective 5-HT reuptake inhibitor, combined with ritanserin, a selective 5-HT2 antagonist, on waking and sleep stages in rats.
    Bjorvatn B; Ursin R
    Behav Brain Res; 1990 Nov; 40(3):239-46. PubMed ID: 2149499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of chronic ritanserin and clorgyline administration on 5-HT2 receptor linked inositol phospholipid hydrolysis.
    Twist EC; Brammer MJ; Stephenson JD; Corn TH; Campbell IC
    Biochem Pharmacol; 1990 Nov; 40(9):2111-6. PubMed ID: 2122900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities.
    Saletu B; Frey R; Krupka M; Anderer P; Grünberger J; See WR
    Sleep; 1991 Oct; 14(5):439-47. PubMed ID: 1836894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam.
    Bressa GM; Marini S; Gregori S
    Int J Clin Pharmacol Res; 1987; 7(2):111-9. PubMed ID: 3108171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chronic ritanserin or clorgyline on amine and metabolite levels in rat frontal cortex.
    Twist EC; Mitchell SN; Corn TH; Campbell IC
    Eur J Pharmacol; 1991 Apr; 196(2):157-60. PubMed ID: 1908389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
    McBride PA; Mann JJ; Nimchinsky E; Cohen ML
    Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic 5-HT2 receptor antagonist treatment alters 5-HT1A autoregulatory control of 5-HT release in rat brain in vivo.
    Kidd EJ; Leysen JE; Marsden CA
    J Neurosci Methods; 1990 Sep; 34(1-3):91-8. PubMed ID: 1701842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of serotonin 5-HT(2A/2C) antagonists on associative learning in the rabbit.
    Welsh SE; Romano AG; Harvey JA
    Psychopharmacology (Berl); 1998 May; 137(2):157-63. PubMed ID: 9630002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
    Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
    Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine-induced inhibition of synaptosomal [3H]5-HT release: possible Ca(2+)-channel inhibition.
    Stauderman KA; Gandhi VC; Jones DJ
    Life Sci; 1992; 50(26):2125-38. PubMed ID: 1608295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5HT2 receptor changes in rat cortex and platelets following chronic ritanserin and clorgyline administration.
    Twist EC; Mitchell S; Brazell C; Stahl SM; Campbell IC
    Biochem Pharmacol; 1990 Jan; 39(1):161-6. PubMed ID: 1688704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of a difference between ketanserin and ritanserin in central vs. peripheral serotonin receptor antagonism.
    Cohen ML; Bloomquist WL; Snoddy HD; Fuller RW
    Life Sci; 1989; 45(13):1185-9. PubMed ID: 2507847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for serotonin-S2 receptor involvement in analgesia in humans.
    Sandrini G; Alfonsi E; De Rysky C; Marini S; Facchinetti F; Nappi G
    Eur J Pharmacol; 1986 Nov; 130(3):311-4. PubMed ID: 3098573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic and serotoninergic influence on duration discrimination and vigilance.
    Rammsayer T
    Pharmacopsychiatry; 1989 Feb; 22 Suppl 1():39-43. PubMed ID: 2717665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of agonists and antagonists of some serotonin-receptor subtypes on memory and their modulation by the 5-HT-uptake inhibitor fluoxetine.
    Petkov VD; Kehayov R
    Acta Physiol Pharmacol Bulg; 1994; 20(3-4):83-90. PubMed ID: 7645408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ritanserin on aversive classical conditioning in humans.
    Hensman R; Guimarães FS; Wang M; Deakin JF
    Psychopharmacology (Berl); 1991; 104(2):220-4. PubMed ID: 1908584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the 5-HT2 receptor antagonist, ritanserin on hyperthermia and depletion of 5-HT in frontal cortex induced by a 5-HT releasing drug, p-chloroamphetamine (PCA) in mice.
    Yamada J; Sugimoto Y; Ohkura M; Inoue K
    Biol Pharm Bull; 2001 Oct; 24(10):1195-7. PubMed ID: 11642332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.